— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.
— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.
— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.
— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.
— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.
— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.
Most Popular
What Starbucks’ ongoing restructuring means for customers and investors
Starbucks Corporation (NASDAQ: SBUX) has launched an extensive restructuring to streamline operations and optimize customer experience. While navigating a difficult operating environment, the coffee giant is working to revive its
Dollar Tree (DLTR) 4Q24 earnings: Family Dollar sale takes center stage in quarterly report
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) were up over 4% on Wednesday following the announcement of the company’s fourth quarter 2024 earnings results. The top and bottom line numbers
Key metrics from Chewy’s (CHWY) Q4 2024 earnings results
Chewy, Inc. (NYSE: CHWY) reported its fourth quarter 2024 earnings results today. Net sales of $3.25 billion were up 14.9% year-over-year. Net income fell 29% to $22.8 million, or $0.05
